Terminated
OBSERVATIONAL
NCT01579695
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
Interventions
Name:
Tesamorelin for injection
Type:
DRUG
Description:
Daily 2 mg subcutaneous injections of Tesamorelin
Primary Outcomes
Measure:
Time to development of malignancies in HIV-infected subjects with abdominal lipohypertrophy exposed to EGRIFTA® vs. concurrent, comparable control group not exposed to EGRIFTA®
TimeFrame:
10 years
Description:
Trial Information
NCT ID
NCT01579695
Status
Terminated
Study Type
OBSERVATIONAL
Sponsor
Theratechnologies
Last Updated
December 15, 2025